Shree Ganesh Rem Stock Price Today (NSE: 540737)
Fundamental Score
Shree Ganesh Rem Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Shree Ganesh Rem share price today is ₹652.85, up +1.06% on NSE/BSE as of 7 August 2026. Shree Ganesh Rem (540737) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹858.90 (Cr). The 52-week high for 540737 share price is ₹759.00 and the 52-week low is ₹381.10. At a P/E ratio of 48.33x, 540737 is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.53% and a debt-to-equity ratio of 0.19.
Shree Ganesh Rem Share Price Chart — NSE/BSE Historical Performance
Shree Ganesh Rem share price chart: 2.98% return over the past month. 52-week high ₹759.00, 52-week low ₹381.10.
Shree Ganesh Rem — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹653.00 | ₹661.00 | ₹640.00 | ₹652.85 | 6.07K (Cr) | |
| ₹620.00 | ₹662.00 | ₹600.00 | ₹646.00 | 6.28K (Cr) | |
| ₹645.80 | ₹660.00 | ₹618.00 | ₹622.45 | 7.83K (Cr) | |
| ₹635.00 | ₹649.00 | ₹635.00 | ₹645.80 | 1.81K (Cr) | |
| ₹659.70 | ₹684.00 | ₹600.00 | ₹633.00 | 18.67K (Cr) | |
| ₹611.05 | ₹660.00 | ₹611.05 | ₹654.20 | 4.01K (Cr) | |
| ₹633.00 | ₹640.05 | ₹600.00 | ₹611.90 | 6.73K (Cr) | |
| ₹633.05 | ₹638.95 | ₹616.05 | ₹621.45 | 5.88K (Cr) | |
| ₹646.00 | ₹659.70 | ₹621.70 | ₹640.40 | 2.35K (Cr) | |
| ₹656.95 | ₹657.00 | ₹634.00 | ₹643.00 | 1.93K (Cr) |
Shree Ganesh Rem — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹635.00 | ₹662.00 | ₹600.00 | ₹652.85 | +2.81% | |
| ₹639.30 | ₹715.00 | ₹600.00 | ₹633.00 | -0.99% | |
| ₹648.00 | ₹759.00 | ₹526.65 | ₹635.25 | -1.97% | |
| ₹482.15 | ₹665.00 | ₹480.05 | ₹649.35 | +34.68% | |
| ₹430.00 | ₹551.00 | ₹425.00 | ₹514.65 | +19.69% | |
| ₹505.00 | ₹590.00 | ₹414.00 | ₹420.05 | -16.82% | |
| ₹419.05 | ₹548.00 | ₹412.05 | ₹512.20 | +22.23% | |
| ₹461.40 | ₹481.35 | ₹381.10 | ₹417.95 | -9.42% | |
| ₹467.45 | ₹480.20 | ₹418.00 | ₹463.20 | -0.91% | |
| ₹499.90 | ₹499.90 | ₹442.10 | ₹467.45 | -6.49% | |
| ₹513.90 | ₹535.00 | ₹478.50 | ₹496.00 | -3.48% | |
| ₹600.00 | ₹609.00 | ₹494.95 | ₹513.90 | -14.35% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Shree Ganesh Rem Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Shree Ganesh Rem Fundamental Analysis & Valuation Benchmarking
Educational evaluation of 540737 across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (31.09%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (35.90%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (17.38% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.75x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (72.84%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 48.33x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Negative Free Cash Flow (₹-19.97 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Shree Ganesh Rem vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Shree Ganesh Rem with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
49.4/100 | ₹652.85₹653 | ₹858.90₹858.90 | 48.33Average 48.3 Average | 11.53%Average 11.53% Average | 14.61%Average 14.61% Average | 0.19Excellent 0.2 Excellent | 12.76%Good 12.76% Good | 17.38%Excellent 17.38% Excellent | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Shree Ganesh Rem Quarterly Performance
Latest quarterly metrics for 540737 — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
35.90%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-5.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
17.38%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.76%
Compounded annual net profit growth over 5 years
Shree Ganesh Rem Technical Indicators
SMA 50, SMA 200, RSI and volume signals for 540737 — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Shree Ganesh Rem Financial Statements
Annual income statement, balance sheet and cash flow for Shree Ganesh Rem (540737) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Shree Ganesh Rem
About 540737 (Shree Ganesh Rem)
Shree Ganesh Rem (540737) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current... market capitalisation of ₹858.90 (Cr). Shree Ganesh Rem has delivered a Return on Equity (ROE) of 11.53% and a ROCE of 14.61%. The debt-to-equity ratio stands at 0.19, reflecting the company's capital structure. Investors tracking 540737 share price can monitor key metrics including P/E ratio, promoter holding of 72.84%, and quarterly earnings growth.
Company Details
540737 Share Price: Frequently Asked Questions
What is the current share price of Shree Ganesh Rem?
Shree Ganesh Rem (540737) trades at ₹652.85 on BSE. Market cap ₹858.90 (Cr). Educational data only.
What is the P/E ratio of Shree Ganesh Rem?
Shree Ganesh Rem has a P/E of 48.33x vs industry average 34.89x.
What is the Bull Run score for Shree Ganesh Rem?
Shree Ganesh Rem has a Bull Run score of 49.4/100 based on 25+ financial parameters.
Does Shree Ganesh Rem pay dividends?
Shree Ganesh Rem has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Shree Ganesh Rem?
Shree Ganesh Rem has ROE of 11.53%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Shree Ganesh Rem?
Shree Ganesh Rem has debt-to-equity of 0.19.
Is Shree Ganesh Rem a good investment?
Bull Run gives Shree Ganesh Rem a score of 49.4/100. This is not investment advice — consult a SEBI-registered advisor.